Brokerages Set Novavax, Inc. (NASDAQ:NVAX) PT at $17.83

Novavax, Inc. (NASDAQ:NVAX - Get Free Report) has earned a consensus rating of "Hold" from the six ratings firms that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $17.83.

Separately, HC Wainwright reiterated a "buy" rating and issued a $19.00 price objective on shares of Novavax in a report on Tuesday, December 10th.

Insider Transactions at Novavax

In related news, Director Rachel K. King sold 4,150 shares of the company's stock in a transaction on Friday, December 13th. The shares were sold at an average price of $9.02, for a total transaction of $37,433.00. Following the completion of the transaction, the director now directly owns 14,770 shares in the company, valued at $133,225.40. This represents a 21.93 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director James F. Young sold 5,400 shares of the firm's stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $8.00, for a total transaction of $43,200.00. Following the completion of the sale, the director now owns 51,760 shares in the company, valued at $414,080. This represents a 9.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 14,150 shares of company stock worth $119,641 over the last three months. 1.00% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Novavax

Several large investors have recently added to or reduced their stakes in NVAX. Vanguard Group Inc. increased its position in shares of Novavax by 1.9% during the fourth quarter. Vanguard Group Inc. now owns 15,726,250 shares of the biopharmaceutical company's stock valued at $126,439,000 after purchasing an additional 296,181 shares during the period. Shah Capital Management boosted its stake in Novavax by 13.6% during the fourth quarter. Shah Capital Management now owns 11,148,846 shares of the biopharmaceutical company's stock worth $89,637,000 after buying an additional 1,333,305 shares in the last quarter. State Street Corp increased its holdings in Novavax by 26.7% in the 3rd quarter. State Street Corp now owns 7,687,951 shares of the biopharmaceutical company's stock valued at $97,099,000 after buying an additional 1,621,772 shares during the period. Sanofi acquired a new position in shares of Novavax in the 4th quarter valued at $55,319,000. Finally, Geode Capital Management LLC lifted its holdings in shares of Novavax by 4.4% during the 4th quarter. Geode Capital Management LLC now owns 3,657,695 shares of the biopharmaceutical company's stock worth $29,415,000 after acquiring an additional 155,206 shares during the period. Institutional investors and hedge funds own 53.04% of the company's stock.

Novavax Trading Up 3.8 %

NASDAQ NVAX traded up $0.31 during trading on Wednesday, reaching $8.50. The company's stock had a trading volume of 954,855 shares, compared to its average volume of 4,140,767. The business has a 50-day moving average price of $8.72 and a 200-day moving average price of $10.20. Novavax has a 1-year low of $3.81 and a 1-year high of $23.86. The stock has a market capitalization of $1.36 billion, a PE ratio of -3.76, a PEG ratio of 63.06 and a beta of 2.14.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.